Atara Biotherapeutics (NASDAQ:ATRA) Upgraded to “Strong-Buy” at RODMAN&RENSHAW

RODMAN&RENSHAW upgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) to a strong-buy rating in a report published on Friday morning,Zacks.com reports.

Several other equities analysts also recently weighed in on the company. Canaccord Genuity Group raised their target price on Atara Biotherapeutics from $13.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. TD Cowen upgraded shares of Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, Rodman & Renshaw assumed coverage on Atara Biotherapeutics in a research report on Friday. They issued a “buy” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Atara Biotherapeutics has an average rating of “Moderate Buy” and an average target price of $18.75.

Atara Biotherapeutics Trading Up 14.8 %

Shares of ATRA stock opened at $11.40 on Friday. The business’s fifty day simple moving average is $10.80 and its 200-day simple moving average is $9.60. Atara Biotherapeutics has a 12-month low of $6.50 and a 12-month high of $39.50. The company has a market cap of $65.66 million, a PE ratio of -0.44 and a beta of 0.55.

Atara Biotherapeutics (NASDAQ:ATRA) last released its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) EPS for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the prior year, the company posted ($16.50) EPS. On average, equities analysts forecast that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ATRA. Geode Capital Management LLC grew its stake in Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after purchasing an additional 4,043 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the 2nd quarter valued at about $53,000. FMR LLC grew its position in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after buying an additional 7,381 shares in the last quarter. State Street Corp increased its stake in shares of Atara Biotherapeutics by 52.3% during the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after buying an additional 7,680 shares during the period. Finally, Cubist Systematic Strategies LLC acquired a new stake in Atara Biotherapeutics in the second quarter valued at approximately $79,000. 70.90% of the stock is currently owned by hedge funds and other institutional investors.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.